{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(9)"],"submitter":["Smith GHR"],"funding":["ViiV Healthcare and Janssen Research and Development"],"pubmed_abstract":["Background
In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years.Methods
After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/"],"journal":["Open forum infectious diseases"],"pagination":["ofab439"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8454521"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study."],"pmcid":["PMC8454521"],"pubmed_authors":["Henry WK","Zhang F","Khuong-Josses MA","Podzamczer D","Smith KY","Stellbrink HJ","Margolis DA","Jaeger H","Masia MDM","Yazdanpanah Y","McCoig CC","Smith GHR","Bettacchi CJ","Arasteh K","Van Solingen-Ristea R","Richmond GJ","Vandermeulen K","St Clair MH","Spreen WR","Montes-Ramirez ML","Sutton KC"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.","description":"Background
In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years.Methods
After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-26T23:36:13.501Z","creation":"2022-02-11T11:16:19.681Z"},"accession":"S-EPMC8454521","cross_references":{"pubmed":["34557563"],"doi":["10.1093/ofid/ofab439"]}}